

Artemisinin and Derivatives Cancer Studies

Pancreatic Cancer

- (1) Aung W *et al.* Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. *Anticancer Res.* 2011 May;31(5):1549-58.
- (2) Chen H *et al.* Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. *J Cancer Res Clin Oncol.* 2009 Nov 26.
- (3) Chen H *et al.* Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. *Anticancer Drugs.* 2009 Feb;20(2):131-40.
- (4) Du JH *et al.* Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. *Cancer Chemother Pharmacol.* 2009 Aug 19.
- (5) Wang SJ *et al.* Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF- κ B pathway. *Cancer Chemother Pharmacol.* 2011 Dec;68(6):1421-30
- (6) Wang SJ *et al.* Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer. *Zhonghua Wai Ke Za Zhi.* 2010 Apr 1;48(7):530-4.
- (7) Wang SJ *et al.* Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. *Cancer Lett.* 2010 Jul 1;293(1):99-108.
- (8) Youns M *et al.* Gene expression profiling identifies novel key players involved in the cytotoxic effect of artesunate on pancreatic cancer cells. *Biochem Pharmacol.* 2009 Aug 1;78(3):273-83.